Telo Genomics Corp. announced that results of the development, validation and implementation of its machine learning and Artificial Intelligence (AI) modules, used in its TeloView myeloma diagnostic tests, were presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting that took place in Chicago, USA between May 30, 2024 to June 4, 2024. The presented results described the validation and release of Telo's proprietary tool, CellSelect-Pro, that was developed using machine learning and AI platforms, to facilitate high throughput processing of samples while enhancing consistency and accuracy.

The tool will favorably impact the sample processing turn-around-time (TAT) with potential cost savings of 20%-25% versus manual cell selection in the company's TeloView myeloma diagnostic tests. The innovative, proprietary algorithm was developed to identify, quantify and process myeloma plasma cells found in the patients' samples being tested. Over 5,000 myeloma positive and negative cells were used to train the AI algorithm, which was validated by processing over 20 myeloma patients' samples.

CellSelect-Pro achieved accuracy of >90% and percision of >80% in the conducted validation. The tool was successfully implemented into Telo's testing workflows. The primary clinical application for CellSelect-Pro is Telo's product for smoldering multiple myeloma (SMM) patients, TeloViewSMM, offered now in the USA through the Company's SMART program (Smoldering Multiple myeloma Assessment of Risk for Transformation).

CellSelect-Pro was also implemented in the workflow of Telo's active MRD (Minimal Residual Disease) clinical trial for treated multiple myeloma patients, conducted in collaboration with the McGill University, Montreal, Canada.